World Generic Drug Market Outlook 2010-2025

Our new report will show you revenue prospects for the generic drug market from 2010 onwards. Where will the best growth prospects lie, and which companies will be the biggest winners? We provide revenue trends for 2010 to 2025 and discussions to meet your needs. You can have that report today, staying ahead.

Expansion of the generics industry and market will continue. Overall generic drug revenues are growing faster than those of the overall pharma market. Which national markets, therapeutic areas and organisations will hold the best opportunities for generics? We show you technological and commercial potential from 2010 onwards, revealing opportunities and challenges.

Our report will give you present and future revenue values for the generics sector, globally and nationally. You can assess the strengths, weaknesses and revenue trends for generic drugs from 2010 to 2025. We aim to save you time and benefit your work.

We also discuss the opportunities and challenges facing the patented drug sector from 2010 onwards, especially for blockbuster drugs. Changes to healthcare policy worldwide increase the importance of generics. You can discover the sector's prospects today.

You can assess leading national markets for generic drugs (US, Germany, France, UK, Spain, Italy, Japan, India, China, Turkey, Brazil, Mexico, South Korea and Russia). You will receive revenue forecasts and other data. You will also explore policy, legislative matters, pricing and reimbursement and competition.

You can receive discussions of leading companies in the generics sector, with analyses of their activities and prospects. You can examine mergers and acquisitions that will continue shaping the generics sector from 2010. We also show you how leading pharma companies are entering the sector. Our report shows you how generics can affect the pharma industry and its stakeholders from 2010 to 2025.

Industry and market analysis to save you time and aid your decisions

Our new report examines the generic drug sector critically. We harness primary and secondary research to meet your needs. We provide revenue forecasts, market share analyses and other data. We discuss products and strategies. You can discover strengths, weaknesses, opportunities and threats in the sector. We include many tables and figures and an expert interview - shown in the contents lists with this message.


Report Highlights
Companies Listed
Abbott Laboratories
Aché Laboratórios Farmacêuticos
Actavis
Amgen
Andrx Corporation
Apotex
APP Pharmaceuticals
Arrow Group
Asociación Española de Fabricantes de Sustancias y Especialidades Farmacéuticas Genéricas (AESEG)
Assogenerici - Associazione Nazionale Industrie Farmaci Generici
AstraZeneca
Aurobindo Pharma
Barr Pharmaceuticals
Bayer HealthCare
Beijing MedPharm
Blue Cross Blue Shield Association (BCBSA)
BMP Sunstone
Boehringer Ingelheim
Bristol-Myers Squibb
British Generics Manufacturers Association (BGMA)
Cangene Corporation
Celltrion
Centers for Medicare and Medicaid Services
Chon Kun Dang
Cipla
CoGenesys
Congressional Budget Office (CBO)
Daiichi Sankyo
DOC Generici
Dr. Reddy's Laboratories
Eden Biodesign
Egis
Eisai Pharmaceuticals
Eli Lilly
EMS Sigma Pharma
Eon Labs
Eurofarma Laboratorios
European Commission (EC)
European Court of Justice
European Generic Medicines Association (EGA)
European Medicines Agency (EMA/EMEA)
European Union (EU)
Famy Care
Farmacia del Ahorro
Farmacias Similares
Federal Trade Commission (FTC)
Food and Drug Administration (FDA)
Fuji Pharma
Gedeon Richter
Genentech
Generic Pharmaceutical Association (GPhA)
German Association of Pharmacists (ABDA)
GlaxoSmithKline (GSK)
Glenmark Pharmaceuticals
Greenstone (Pfizer)
H. Lundbeck
Hospira
Intas Biopharmaceuticals
IVAX
Johnson & Johnson
Jubilant Organosys
Kowa Pharmaceuticals
Krka
Laboratorios Best
Laboratorios Kendrick
Lareq Pharma
Lek Pharmaceuticals
Lupin Pharmaceuticals
MasterLek
Mayne Pharma
Medi-Mart
Medley Pharmaceuticals
Merck & Co.
Merck KGaA
Mundipharma International
Mylan Pharmaceuticals
Mylan Seiyaku
National Health Service (NHS)
Nichi-Iko
Nippon Chemiphar
Novartis
NOVN. V Hexal
Pfizer
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pharmstandard
Piramal
Pliva
Purdue Pharma
Ranbaxy Laboratories
ratiopharm
Roche
Samsung
Sanborns
Sandoz
Sanofi-Aventis
Sawai Pharmaceuticals
Shire Pharmaceuticals
Sigma Pharmaceuticals
SK Chemicals
Stada Arzneimittel AG
Sun Pharmaceuticals
Taisho Pharmaceutical Industries
Taiyo Pharmaceuticals
Takeda Pharmaceutical Company
Tecnofarma
Teva Pharmaceutical Industries
Topgen
Towa Pharmaceutical
UCB
UK Department of Health
Veropharm
Wal-Mart
Warner Chilcott
Watson Pharmaceuticals
Wockhardt
World Trade Organisation (WTO)
Wyeth
Zentiva
Zydus Cadila
[Studien Infos ausblenden]

1. Executive Summary
1.1 The Generic Drugs Sector: Industry and Market Review
1.2 Research & Analysis Methods
1.3 Chapter Breakdown for this Report

2. Overview of the World Generics Market
2.1 Generic Drugs: An Introduction
2.1.1 Authorised, Branded and True Generics
2.2 'Evergreening'
2.3 Limited Growth in the World Pharmaceutical Market
2.4 Branded Pharmaceuticals: End of a Business Model?
2.5 US Regulations
2.5.1 Obtaining FDA Approval: NDAs and ANDAs
2.5.2 The Hatch-Waxman Act Title 1: Promotion of Generic Drugs
2.5.3 The Hatch-Waxman Act Title 2: Incentives for the Branded Industry
2.5.4 Consequences of the Hatch-Waxman Act
2.5.5 Me First: Timing as a Crucial Factor
2.6 European Regulations
2.6.1 Generics' Entry into the European Markets
2.6.2 Further Protection of Branded Products in the European Markets
2.6.3 Variations Among European Countries
2.6.4 Moving Towards Standardisation
2.6.5 The 8+2+1 Rule
2.7 Japanese Regulations
2.8 Compulsory Licensing
2.9 Generic Drugs: Overview

3. Generic Pharmaceuticals: World Market Forecast 2010-2025
3.1 Generic Products versus Branded Pharmaceuticals
3.2 Overall Sales Forecast 2010-2025
3.3 Global Market Breakdown 2010-2025

4. Leading Companies in the World Generics Market
4.1 Teva Pharmaceutical Industries - Prospects from 2010
4.1.1 ANDAs and Approvals
4.1.2 M&A Activity
4.2 Sandoz - Prospects from 2010
4.3 Mylan - Prospects from 2010
4.4 Apotex - Prospects from 2010
4.5 Hospira - Prospects from 2010
4.6 Watson - Prospects from 2010

5. The US Generics Market 2010-2025
5.1 Analysis of the Current Market
5.2 The US Generics Market: Revenue Forecast 2010-2025
5.3 Regulatory Reform Can Keep the Market Growing
5.3.1 A New Pathway to the US Market for Biosimilars?
5.3.2 Reverse Payments
5.3.3 The ANDA Backlog
5.4 Growing Consumer Acceptance of Generic Medicines
5.5 Leading Companies in the US Generics Market
5.6 Concluding Remarks

6. Leading European Generics Markets 2010-2025
6.1 Analysis of the Current Generics Market in Europe
6.2 Revenue Prospects for European Generics Markets 2010-2025
6.2.1 The Two Categories of European Market
6.2.2 European Pricing Systems and their Effect on Generic Penetration
6.2.3 Patient Co-Payment
6.2.4 Challenges with the European Regulatory Environment
6.3 The German Generics Market
6.3.1 German Generics Market: Sales Forecast 2010-2025
6.3.2 The Future of the German Generics Market
6.4 The French Generics Market
6.4.1 French Generics Market: Sales Forecast 2010-2025
6.4.2 The Future of the French Generics Market
6.5 The UK Generics Market
6.5.1 UK Generics Market: Sales Forecast 2010-2025
6.5.2 Generics Prescribing Linked to Increasing Budgetary Constraints
6.5.3 Reducing Generic Drug Prices: the Drug Tariff System
6.5.4 The Increasing Role of Pharmacists
6.5.5 Easy Entry, Strong Price Competition
6.5.6 The Future of the UK Generics Market
6.6 The Spanish Generics Market
6.6.1 Spanish Generics Market: Sales Forecast 2010-2025
6.6.2 Challenges for the Spanish Market
6.6.3 Prospects for the Spanish Generics Market
6.7 The Italian Generics Market
6.7.1 Italian Generics Market: Sales Forecast 2010-2025
6.7.2 Promoting Generic Penetration
6.7.3 Prospects for the Italian Generics Market
6.8 Concluding Remarks

7. The Japanese Generics Market 2010-2025
7.1 Analysis of the Current Market
7.2 Japanese Generics Market: Sales Forecast 2010-2025
7.3 Government Initiatives Have Driven Market Growth
7.3.1 Mergers and Acquisitions
7.4 Concluding Remarks

8. Emerging Generics Markets 2010-2025
8.1 The EM-7: Pharma's Best Hope?
8.2 M&A as a Tactic for Entering the Generic Drugs Sector
8.3 Turkish Generics Market: Sales Forecast 2010-2025
8.4 Brazilian Generics Market: Sales Forecast 2010-2025
8.5 Mexican Generics Market: Sales Forecast 2010-2025
8.6 South Korean Generics Market: Sales Forecast 2010-2025
8.7 Russian Generics Market: Sales Forecast 2010-2025
8.7.1 Russian Generics Market, 2010-2025
8.7.2 Analysis of the Russian Market
8.8 India - Market Prospects from 2010
8.8.1 Indian Generics Market: Sales Forecast 2010-2025
8.8.2 International Success of India's Pharmaceutical Industry
8.9 China - Market Prospects from 2010
8.9.1 Chinese Generics Market: Sales Forecast 2010-2025
8.9.2 Chinese Generics Market: Discussion of Sector

9. World Generics Market: Strengths, Weaknesses, Opportunities and Threats
9.1 The Generics Sector Will Remain a High-Growth Area
9.2 Generics Offer Limited Profitability?
9.3 Emerging Markets and Generics: The Pharma Industry's Biggest Opportunity?
9.4 The Generic Drug Market's Growth is Assured, but Some Threats Remain

10. Expert Opinion
10.1 Charlie Mayr, Generic Pharmaceutical Association (GPhA)
10.1.1 The Value of the Generics Market
10.1.2 Main Challenges for the US Generics Market
10.1.3 On Authorised Generic Products
10.1.4 On Biogeneric (Biosimilar) Products

11. Conclusions
11.1 The World Generics Market Will Continue to Expand
11.2 The Emerging National Markets Hold Much Promise
11.3 Biosimilars Have Promise, but Difficulties and Uncertainties Remain
11.4 Concluding Remarks

Appendix A: Supplementary Information on the Sector
[Inhaltsverzeichnis ausblenden]

Table 3.1 Overall Generics Market: Sales ($bn), Growth (%), CAGR (%), 2009-2025
Table 3.2 Generics Market by Country: Sales ($bn), Growth (%), CAGR (%), 2009-2025
Table 4.1 Leading Companies in the World Generics Market: Sales ($bn) and Market Shares (%), 2009
Table 5.1 US Generic Drug Market Penetration (%) by Volume, 2000-2009
Table 5.2 US Generic Drug Market Penetration (%) by Revenue, 2000-2009
Table 5.3 US Generics Market: Sales ($bn), Growth (%), CAGR (%), 2009-2025
Table 6.1 German Generics Market: Sales ($bn), Growth (%), CAGR (%), 2009-2025
Table 6.2 French Generics Market: Sales ($bn), Growth (%), CAGR (%), 2009-2025
Table 6.3 UK Generics Market: Sales ($bn), Growth (%), CAGR (%), 2009-2025
Table 6.4 Spanish Generics Market: Sales ($bn), Growth (%), CAGR (%), 2009-2025
Table 6.5 Italian Generics Market: Sales ($bn), Growth (%), CAGR (%), 2009-2025
Table 7.1 Japanese Generics Market: Sales ($bn), Growth (%), CAGR (%), 2009-2025
Table 8.1 Turkish Generics Market: Sales ($bn), Growth (%), CAGR (%), 2009-2025
Table 8.2 Brazilian Generics Market: Sales ($bn), Growth (%), CAGR (%), 2009-2025
Table 8.3 Mexican Generics Market: Sales ($bn), Growth (%), CAGR (%), 2009-2025
Table 8.4 South Korean Generics Market: Sales ($bn), Growth (%), CAGR (%), 2009-2025
Table 8.5 Russian Generics Market: Sales ($bn), Growth (%), CAGR (%), 2009-2025
Table 8.6 Indian Generics Market: Sales ($bn), Growth (%), CAGR (%), 2009-2025
Table 8.7 Chinese Generics Market: Sales ($bn), Growth (%), CAGR (%), 2009-2025
Table 9.1 SWOT Analysis of the World Generic Drug Market, 2010
Table A.1 Main Patent Expiries, 2009-2014
Table A.2 Main Patent Expiries by Number, 2009-2014
Table A.3 Main Patent Expiries, 2009
Table A.4 Main Patent Expiries, 2010
Table A.5 Main Patent Expiries, 2011
Table A.6 Main Patent Expiries, 2012
Table A.7 Main Patent Expiries, 2013
Table A.8 Main Patent Expiries, 2014

Figure 3.1 Audited and Unaudited Generic Drug Sales ($bn), 2009
Figure 3.2 Overall Generics Market: Sales ($bn), 2009-2025
Figure 3.3 Overall Generics Market: Annual Growth (%), 2009-2025
Figure 4.1 Leading Companies in the World Generics Market ($bn), 2009
Figure 5.1 US Generic Drug Market Penetration (%) by Volume, 2000-2009
Figure 5.2 US Generic Drug Market Penetration (%) by Revenue, 2000-2009
Figure 5.3 US Generics Market: Sales ($bn), 2009-2025
Figure 5.4 ANDAs Received, Approved and Tentatively Approved, 2005-2009
Figure 5.5 Leading Companies in the US Generics Market by Prescription Volume, 2009
Figure 6.1 German Generics Market: Sales ($bn), 2009-2025
Figure 6.2 French Generics Market: Sales ($bn), 2009-2025
Figure 6.3 UK Generics Market: Sales ($bn), 2009-2025
Figure 6.4 Spanish Generics Market: Sales ($bn), 2009-2025
Figure 6.5 Italian Generics Market: Sales ($bn), 2009-2025
Figure 7.1 Japanese Generics Market: Sales ($bn), 2009-2025
Figure 8.1 Turkish Generics Market: Sales ($bn), 2009-2025
Figure 8.2 Brazilian Generics Market: Sales ($bn), 2009-202
Figure 8.3 Mexican Generics Market: Sales ($bn), 2009-2025
Figure 8.4 South Korean Generics Market: Sales ($bn), 2009-2025
Figure 8.5 Russian Generics Market: Sales ($bn), 2009-2025
Figure 8.6 Indian Generics Market: Sales ($bn), 2009-2025
Figure 8.7 Chinese Generics Market: Sales ($bn), 2009-2025
Figure 11.1 Generics Market: Overall Sales Prospects ($bn), 2009-2025
[Tabellenverzeichnis ausblenden]